Restructuring Charges

12 Months Ended

Dec. 31, 2023

RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, fixed assets impairments, and related consulting fees. The following reflects our restructuring activity (in millions):


	Year Ended
	December 31, 2023
	Supply Chain Reinvention		HRA Pharma Integration		Project Energize		Other Initiatives		Total
Beginning balance	$	2.2	$	13.3	$	—	$	4.3	$	19.8
Additional charges	28.0		4.2		7.4		2.6		42.2
Payments	(13.4)		(10.9)		(4.5)		(4.6)		(33.4)
Non-cash adjustments	(16.1)		0.2		—		(0.5)		(16.4)
Ending balance	$	0.7	$	6.8	$	2.9	$	1.8	$	12.2


	Year Ended
	December 31, 2022
	Supply Chain Reinvention		Other Initiatives		Total
Beginning balance	$	—	$	6.9	$	6.9
Additional charges	24.3		18.2		42.5
Payments	(22.1)		(7.7)		(29.8)
Non-cash adjustments	—		0.2		0.2
Ending balance	$	2.2	$	17.6	$	19.8


	Year Ended
	December 31, 2021
	Other Initiatives		Total
Beginning balance	$	9.1	$	9.1
Additional charges	16.9		16.9
Payments	(19.0)		(19.0)
Non-cash adjustments	(0.1)		(0.1)
Ending balance	$	6.9	$	6.9

The charges incurred during the year ended December 31, 2023 were primarily associated with actions taken on supply chain restructuring, Project Energize and HRA integration activities. Charges related to supply chain restructuring included an asset impairment of $16.1 million. The charges incurred during the year ended December 31, 2022 were primarily associated with actions taken on supply chain restructuring and HRA integration activities. The charges incurred during the year ended December 31, 2021 were primarily associated with actions takes to streamline the organization.

Of the amount recorded during the year ended December 31, 2023, $21.4 million was related to our CSCI segment, due primarily to supply chain restructuring and HRA Pharma integration initiatives and $13.0 million was related to our CSCA segment, due primarily to supply chain restructuring. Of the amount recorded during the year ended December 31, 2022, $29.4 million was related to our CSCI segment, due primarily to supply chain restructuring and HRA integration initiatives, and $2.5 million was allocated to our CSCA segment, due primarily to actions taken to streamline the organization. For year ended December 31, 2021, $6.1 million related to our CSCI segment also due primarily to various integration initiatives and $7.9 million was allocated to our CSCA segment, due primarily to actions taken to streamline the organization. The remaining charges for all years were reported in our Unallocated segment. There were no other material restructuring programs in any of the periods presented.

All charges are recorded in restructuring expense on the Consolidated Financial Statements. The remaining $12.2 million liability for employee severance benefits is expected to be paid mostly within the next year.